A review of albumin binding in CKD

被引:105
作者
Meijers, Bjoern K. I. [1 ]
Bammens, Bert [1 ]
Verbeke, Kristin [2 ]
Evenepoel, Pieter [1 ]
机构
[1] Univ Hosp Leuven, Dept Med, Div Nephrol, Louvain, Belgium
[2] Univ Hosp Leuven, Dept Gastrointest Res, Louvain, Belgium
关键词
albumin; albumin binding; protein binding; chronic kidney disease; review;
D O I
10.1053/j.ajkd.2007.12.035
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Hypoalbuminemia is associated with excess mortality in patients with kidney disease. Albumin is an important oxidant scavenger and an abundant carrier protein for numerous endogenous and exogenous compounds. Several specific binding sites for anionic, neutral, and cationic ligands were described. Overall, the extent of binding depends on the ligand and albumin concentration, albumin-binding affinity, and presence of competing ligands. Chronic kidney disease affects all these determinants. This may result in altered pharmacokinetics and increased risk of toxicity. Renal clearance of albumin-bound solutes mainly depends on tubular clearance. Dialytic clearance by means of conventional hemodialysis/hemofiltration and peritoneal dialysis is limited. Other epuration techniques combining hemodialysis with adsorption have been developed. However, the benefit of these techniques remains to be proved.
引用
收藏
页码:839 / 850
页数:12
相关论文
共 86 条
[1]   Distribution of cyclosporin in organ transplant recipients [J].
Akhlaghi, F ;
Trull, AK .
CLINICAL PHARMACOKINETICS, 2002, 41 (09) :615-637
[2]   Effect of oxidative stress on the structure and function of human serum albumin [J].
Anraku, M ;
Yamasaki, K ;
Maruyama, T ;
Kragh-Hansen, U ;
Otagiri, M .
PHARMACEUTICAL RESEARCH, 2001, 18 (05) :632-639
[3]   Urinalysis in Western culture: A brief history [J].
Armstrong, J. A. .
KIDNEY INTERNATIONAL, 2007, 71 (05) :384-387
[4]   Serum total homocysteine concentration before and after renal transplantation [J].
Arnadottir, M ;
Hultberg, B ;
Wahlberg, J ;
Fellström, B ;
Dimény, E .
KIDNEY INTERNATIONAL, 1998, 54 (04) :1380-1384
[5]   The binding of selected therapeutic drugs to human serum α-1 acid glycoprotein and to human serum albumin in vitro [J].
Bailey, DN ;
Briggs, JR .
THERAPEUTIC DRUG MONITORING, 2004, 26 (01) :40-43
[6]   Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms [J].
Bammens, B ;
Evenepoel, P ;
Verbeke, K ;
Vanrenterghem, Y .
KIDNEY INTERNATIONAL, 2003, 64 (06) :2238-2243
[7]   Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients [J].
Bammens, B ;
Evenepoel, P ;
Keuleers, H ;
Verbeke, K ;
Vanrenterghem, Y .
KIDNEY INTERNATIONAL, 2006, 69 (06) :1081-1087
[8]  
BEERMANN B, 1984, ACTA PHARMACOL TOX, V54, P17
[9]   Changes in plasma protein binding have little clinical relevance [J].
Benet, LZ ;
Hoener, BA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) :115-121
[10]   Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus [J].
Berg, TJ ;
Bangstad, HJ ;
Torjesen, PA ;
Osterby, R ;
Bucala, R ;
Hanssen, KF .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (06) :661-665